The cost to taxpayers could be enormous.Sales growth of Zepbound in the U.S. has been constrained by rules that bar Medicare, ...
The number of layoffs in the U.S. pharmaceutical industry exceeded 14,000 last year, a 9% increase from 2023 ...
The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback